« Return to News | CROs/Service Providers

Covance Expands Presence in Ukraine, Slovakia and Israel

Wednesday, February 4, 2009 10:00 AM

Covance opened three new clinical development offices in Central and Eastern Europe and the Middle East to speed clinical trials and develop strategic relationships in those areas.

Covance has been providing services in Central and Eastern Europe since 1994 and in Israel since 1995.

The new offices are located in Kiev, Ukraine; Bratislava, Slovakia; and Tel Aviv, Israel. The Kiev and Bratislava offices will support staff and the CRO’s regional network of field-based clinical research associates (CRAs). The Israel office will serve as the center of operations for Covance’s staff in Greece and Turkey and the Middle East (Israel and Egypt).

"We will continue moving forward with our strategy to expand into geographies that align our therapeutic focus with investigators that consistently demonstrate high-quality results, regulatory compliance, and enrollment performance to meet the current and future clinical research needs of our clients,” said Robert Davie, Ph.D., vice president and general manager, clinical development services Europe, Covance, in a company statement.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.